Its proprietary technology enables it to manufacture active immunotherapy products that are designed to stimulate a patient''s immune system to mount a specific and sustained response to disease.
The company’s product candidate, FavId, is an active immunotherapy used for the treatment of indolent B-cell nonHodgkin''s lymphoma (NHL) that is based upon genetic information extracted from a patient''s tumor.
Favrille is developing a second product candidate, FAV-201, for the treatment of T-cell lymphoma.
It also intends to initiate preclinical studies to identify additional product candidates for the treatment of autoimmune diseases, with an initial focus on multiple sclerosis.
Favrille was co-founded by Daniel P.
Gold and Bob Shopes in 2000.
The company is headquartered in San Diego, California.
